Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements
US6881732B2 · kind B2 · utility
2Cited by
6References
7Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | Jun 13, 2002 |
| Grant date | Apr 19, 2005 |
| Priority date | — |
| Expiry date | Jun 13, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds that demonstrate chelation affinity and selectivity for first transition series elements are administered to patients suffering from such conditions as ischemia, prolonged seizures and trauma to provide neuroprotection, cardioprotection, or both. These compounds when administered form complexes with chelatable iron and copper cations and thereby mitigate the ability of these cations to catalyze Haber-Weiss reactions that form toxic hydroxy free radicals that cause tissue injury. These compounds also form complexes with chelatable zinc cations thereby inhibiting the cytotoxicity associated with excess chelatable zinc.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.